SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-020588
Filing Date
2023-05-10
Accepted
2023-05-10 16:28:40
Documents
14
Period of Report
2023-05-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tnya-20230510.htm   iXBRL 8-K 68911
2 EX-99.1 tnya-ex99_1.htm EX-99 142719
3 GRAPHIC img92481827_0.jpg GRAPHIC 6181
  Complete submission text file 0000950170-23-020588.txt   354818

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tnya-20230510.xsd EX-101.SCH 2494
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tnya-20230510_lab.xml EX-101.LAB 13887
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tnya-20230510_pre.xml EX-101.PRE 11445
8 EXTRACTED XBRL INSTANCE DOCUMENT tnya-20230510_htm.xml XML 4907
Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Filer) CIK: 0001858848 (see all company filings)

IRS No.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40656 | Film No.: 23906929
SIC: 2836 Biological Products, (No Diagnostic Substances)